Claims
- 1. An attenuated genetically engineered influenza A virus with an interferon-inducing phenotype containing a knockout of the NS1 gene segment.
- 2. An attenuated genetically engineered influenza A virus containing a deletion of the entire NS1 gene segment which is capable of infecting and replicating in an interferon (IFN) deficient cell line.
- 3. The attenuated virus of claim 1 or 2 which further encodes a heterologous sequence.
- 4. The attenuated virus of claim 1 or 2 in which the heterologous sequence encodes a viral antigenic peptide.
- 5. The attenuated virus of claim 1 or 2 in which the heterologous sequence encodes a tumor antigenic peptide.
- 6. A vaccine comprising an attenuated genetically engineered influenza A virus containing a complete deletion in its NS1 gene segment in a suitable pharmaceutical formulation.
- 7. The vaccine of claim 6 which is formulated for intranasal delivery.
- 8. A method of vaccination comprising administering to a subject the vaccine of claim 6.
Government Interests
[0001] The work reflected in this application was supported, in part, by a grant from the National Institutes of Health, and the Government may have certain rights in the invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60089103 |
Jun 1998 |
US |
Continuations (2)
|
Number |
Date |
Country |
Parent |
09631277 |
Aug 2000 |
US |
Child |
10314569 |
Dec 2002 |
US |
Parent |
09332287 |
Jun 1999 |
US |
Child |
09631277 |
Aug 2000 |
US |